Merck & Co., Inc. $MRK Shares Sold by QV Investors Inc.

QV Investors Inc. reduced its position in Merck & Co., Inc. (NYSE:MRK) by 37.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 11,507 shares of the company’s stock after selling 6,860 shares during the quarter. QV Investors Inc.’s holdings in Merck & Co., Inc. were worth $1,672,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after buying an additional 1,073,507 shares during the period. State Street Corp raised its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after acquiring an additional 1,087,583 shares during the period. Wellington Management Group LLP raised its position in shares of Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after acquiring an additional 1,934,312 shares during the period. Bank of America Corp DE raised its position in shares of Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after acquiring an additional 2,919,780 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Merck & Co., Inc. by 23.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock valued at $1,858,938,000 after acquiring an additional 2,969,856 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. This represents a 63.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Maraldo sold 18,706 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last quarter. Corporate insiders own 0.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on MRK shares. Rothschild & Co Redburn upped their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 6th. Citigroup boosted their price objective on Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a research report on Monday, October 12th. Royal Bank Of Canada reduced their target price on Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a research note on Monday, October 12th. Guggenheim increased their target price on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. Finally, HSBC increased their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Seventeen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average price target of $151.92.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s newer cancer treatments and encouraging Phase 3 melanoma results may help broaden its oncology franchise and reduce reliance on Keytruda. Investors are assessing whether these products can become meaningful growth drivers before Keytruda faces patent-related competition. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Positive Sentiment: The company’s diversified drug portfolio, research investments and dividend—approximately a 2.4% yield—provide support for investors seeking income while waiting for newer therapies to offset future Keytruda pressure. Merck also previously raised its 2026 sales outlook. Merck’s 2.4% Dividend Yield
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in cash, including $20 per American depositary share. The deal could strengthen the German company’s pipeline, but Merck KGaA is a separate company from U.S.-listed Merck & Co. (MRK), so the transaction does not directly affect MRK’s earnings or stock.
• Negative Sentiment: Keytruda’s concentration creates a significant patent-cliff risk. New treatments must scale rapidly enough to replace a large portion of sales and profits when competition arrives, adding uncertainty to Merck’s valuation and long-term growth outlook. Merck Has New Cancer Treatments
• Negative Sentiment: Exchange-traded funds were reported as net sellers of MRK, indicating some short-term institutional or systematic selling pressure despite the company’s underlying growth initiatives. ETFs Are Net Sellers of Merck

Merck & Co., Inc. Trading Up 3.2%

Shares of Merck & Co., Inc. stock opened at $148.19 on Wednesday. The stock has a market cap of $365.62 billion, a P/E ratio of 118.55, a P/E/G ratio of 6.64 and a beta of 0.21. The stock’s 50 day simple moving average is $146.22 and its 200-day simple moving average is $129.67. Merck & Co., Inc. has a 1-year low of $82.01 and a 1-year high of $156.92. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter last year, the firm earned $2.13 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were paid a dividend of $0.85 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.